GMP News and Research

RSS

More men than women discontinue medications due to side effects

Men are more likely than women to discontinue a medication due to side effects. More and more men are diagnosed with age-related issues like enlarged prostate and men are being prescribed medications that have side effects. These side effects often cause men to say "NO." In the U.S. and Canada, Prostate prescriptions dominate the treatment of enlarged prostate.

10 Sep 2010

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

Florida-based biopharmaceutical company Oragenics, Inc. has announced the continued retail expansion of its oral care probiotics EvoraPlus and EvoraKids™ with an initial order from Harris Teeter. It is anticipated that the products will be available at Harris Teeter stores in September 2010.

10 Sep 2010

GE Healthcare to showcase molecular imaging portfolio at WMIC

Reinforcing its commitment to researchers and clinicians, GE Healthcare, a unit of General Electric Company is showcasing a comprehensive molecular imaging portfolio—encompassing tracer development, pre-clinical imaging and highly advanced imaging equipment— to provide insight into the origins of disease, at the World Molecular Imaging Congress (WMIC), Booth #212, September 8 through 11 in Kyoto, Japan.

10 Sep 2010

Edimer Pharmaceuticals, CMC Biologics execute manufacturing contract to develop EDI200 recombinant protein

Edimer Pharmaceuticals and CMC Biologics today announce the execution of a manufacturing contract to support the development of EDI200, a clinical-stage recombinant protein for the treatment of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), a rare genetic disease with orphan designation in the USA and Europe.

10 Sep 2010

Vela Laboratories renews GMP certificate for analytical and Quality Control laboratories

Vela Laboratories, a provider of analytical services to the global biopharmaceutical industry, today announced the renewal of the GMP certificate for its analytical and Quality Control laboratories until 2013.

8 Sep 2010

Oragenics launches oral care probiotic products through GNC Stores

Florida-based biopharmaceutical company Oragenics, Inc. announced today that its oral care probiotic EvoraPlus® is now expected to be available at corporate-owned GNC stores nationwide. In addition, GNC has included Oragenics' oral care probiotic for children, EvoraKids™, in its concept stores and on GNC.com.

7 Sep 2010

Protagen AG announces € 10.0 Million for second round of finance totaling

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis announced today a second round of finance totalling a volume of € 10.0 Million.

7 Sep 2010

EQP program helps healthcare professionals identify quality of dietary supplements

Not all supplements are created equally but Emerson Ecologics, the largest provider of dietary supplements and services to healthcare professionals, is taking aggressive steps to make it more clear to healthcare professionals and their patients which manufacturers to trust when it comes to a supplement's purity, identity and potency.

3 Sep 2010

Project GreenVax to acquire XDR GMP single-use production bioreactors from Xcellerex

Xcellerex, Inc. announced today that Project GreenVax has agreed to acquire XDR GMP single-use production bioreactors from Xcellerex. The systems will be deployed in a new facility currently under construction in Bryan, Texas. Project GreenVax is spearheaded by Texas Plant-Expressed Vaccine Consortium, which consists of G-Con, LLC and The Texas A&M University System. Financial terms were not disclosed.

31 Aug 2010

China PharmaHub and Chengdu Yongkon Pharmacy sign cooperation agreement

China PharmaHub Corp., recently merged with World Wide Relics, which will be shortly changing its name to China PharmaHub Corp, is proud to announce it has signed a cooperation agreement with Chengdu Yongkon Pharmacy Co. Ltd., a pharmaceutical company based in Sichuan, with an established sales network of over 2600 hospitals in China.

18 Aug 2010

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today its unaudited financial results for the three-month and six-month periods ended June 30, 2010.

16 Aug 2010

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

Protagen AG, a specialist for in-vitro diagnostics and GMP-compliant protein analysis, announced today that it received a Notice of Allowance by the Japanese Patent Office stating a favourable decision for the patent application 2000-547262 developed at the Max-Planck Institute for Molecular Genetics in Berlin, Germany. This patent claims broadly a method for identifying and selecting clones relating to the basic UNIclone® technology and is already granted in Europe with the publication number EP1073770 B1.

11 Aug 2010

China Sky One second-quarter 2010 total revenues up 26.7%

China Sky One Medical, Inc., a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China, today announced record financial results for the second quarter of 2010.

10 Aug 2010

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Hemispherx Biopharma, Inc. announced its financial results for the three months ended June 30, 2010. The net loss (including non-cash expenses) for the 2nd fiscal quarter was approximately $3,676,000 or $0.03 per share compared to a loss of approximately $3,870,000 or $0.04 per share for the same period in 2009.

7 Aug 2010

Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers

Glycotope GmbH, a leading glycobiology company, has received regulatory approval by German and Italian regulatory authorities for a Phase I study of Glycotope´s next generation antibody CetuGEX™ (GT-MAB 5.2-GEX) for the treatment of various solid cancers.

4 Aug 2010

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

Today, Formatech, Inc. announced that it has selected Femta's FM101 therapeutic candidate to be enrolled in its Fillanthropy Program. Under this program, Formatech will donate the services required to aseptically fill and finish one lot of the drug candidate for use in support of Femta's upcoming clinical trials.

31 Jul 2010

SynCo Bio Partners extends collaboration with Versartis

SynCo Bio Partners today announced an extension of its successful collaboration with Versartis, Inc. following the recent initiation of a Phase 1 clinical trial in type 2 diabetes mellitus (T2DM) patients with monthly dosing of VRS-859. This news comes less than 12 months since the parties entered into a strategic partnership to manufacture Versartis' lead product VRS-859 (exenatide-XTEN).

30 Jul 2010

Novartis launches new OTC children's liquid acetaminophen product

Novartis announces the introduction of Triaminic™ Fever Reducer Pain Reliever, the only branded over-the-counter children's liquid acetaminophen product currently available nationwide in the US. Triaminic® now offers parents a product that combines the pain relieving and fever-reducing power of acetaminophen with the brand that has been trusted by pediatricians and parents for more than 50 years.

27 Jul 2010

Canon Communications to redesign NutritionalOutlook for quick access to relevant content

Today, at the IFT Annual Meeting and Food Expo, the largest annual food science forum and exposition in the world, Canon Communications LLC announced it is in the process of a redesign of NutritionalOutlook.com, the leading online resource for manufacturers of dietary supplements and healthy foods. The website redesign, featuring new content, qualified supplier search, community-building tools, and nutraceutical industry resources, will launch in fall 2010.

22 Jul 2010

Sinobiopharma, Xianfeng enter agreement to manufacture, co-market Clindamycin and L-alanyl-L-glutamine

Sinobiopharma, Inc. is pleased to announce that it has signed an agreement with Anhui Xianfeng Pharmaceuticals Co., Ltd to manufacture and co-market Clindamycin, an antibiotic, and L-alanyl-L-glutamine, a parenteral nutrition.

21 Jul 2010

GMP News and Research

More men than women discontinue medications due to side effects

Harris Teeter to distribute Oragenics' EvoraPlus and EvoraKids oral care probiotics

GE Healthcare to showcase molecular imaging portfolio at WMIC

Edimer Pharmaceuticals, CMC Biologics execute manufacturing contract to develop EDI200 recombinant protein

Vela Laboratories renews GMP certificate for analytical and Quality Control laboratories

Oragenics launches oral care probiotic products through GNC Stores

Protagen AG announces € 10.0 Million for second round of finance totaling

EQP program helps healthcare professionals identify quality of dietary supplements

Project GreenVax to acquire XDR GMP single-use production bioreactors from Xcellerex

China PharmaHub and Chengdu Yongkon Pharmacy sign cooperation agreement

Sinovac Biotech second-quarter 2010 sales increase 131% to $10.3 million

Protagen granted Notice of Allowance in Japan for key method patent for identifying and selecting clones

China Sky One second-quarter 2010 total revenues up 26.7%

Hemispherx Biopharma second-quarter net loss decreases to $3.67 million

Glycotope receives German, Italian regulatory approval for CetuGEX Phase I study for solid cancers

Formatech selects Femta's FM101 therapeutic candidate for Fillanthropy program

SynCo Bio Partners extends collaboration with Versartis

Novartis launches new OTC children's liquid acetaminophen product

Canon Communications to redesign NutritionalOutlook for quick access to relevant content

Sinobiopharma, Xianfeng enter agreement to manufacture, co-market Clindamycin and L-alanyl-L-glutamine

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News